Mark Walport

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sir Mark Walport
Sir Mark Walport (8656569975).jpg
Born Mark Jeremy Walport
(1953-01-25) 25 January 1953 (age 63)[1]
London
Residence United Kingdom
Citizenship United Kingdom
Fields Immunology, Rheumatology
Institutions
Alma mater University of Cambridge[1]
Thesis The biology of complement receptors (1986)
Doctoral advisor Peter Lachmann[2]
Known for
Notable awards
Spouse Julia Elizabeth Neild (m. 1986)[1]
Children one son, three daughters[1]
Website
www.gov.uk/government/people/mark-walport

Sir Mark Jeremy Walport FRS FRCP FRCPath FMedSci (born 25 January 1953[1][6]) is a medical scientist and the Government Chief Scientific Adviser in the United Kingdom.[4][7][8][9][10][11][12][13][14]

Education[edit]

Walport is the son of a general practitioner and was born in London. He was educated at St Paul's School, London,[1] studied medicine at Clare College, Cambridge, and completed his clinical training at Hammersmith, Guy's and Brompton Hospitals in London.[6][15] He was awarded a PhD for research into complement receptors under the supervision of Peter Lachmann in 1986 at the University of Cambridge.[16]

Career[edit]

Previously Walport was Director of the Wellcome Trust from 2003 to 2013.[3] Before this, he was Professor of Medicine (from 1991) and Head of the Division of Medicine (from 1997) at Imperial College London,[6] where he led a research team that focused on the immunology and genetics of rheumatic diseases.[17][18][19][20][21][22][23][24]

Walport was appointed to be the twelfth Government Chief Scientific Adviser in 2013, succeeding Sir John Beddington. As of September 2015, in this role Walport was paid a salary of between £155,000 and £159,999, making him one of the 328 most highly paid people in the British public sector at that time.[25]

Honours[edit]

Walport was knighted in the 2009 New Year Honours list for services to medical research. He was elected a Fellow of the Royal Society in 2011.[5][6] His nomination for the Royal Society reads:

References[edit]

  1. ^ a b c d e f WALPORT, Sir Mark (Jeremy). Who's Who 2015 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc.  (subscription required)
  2. ^ Reed, Tanya (11 July 2003). "Wellcome to a new beginning". Reporter: The newspaper of Imperial College London (131). 
  3. ^ a b Vogel, G. (2003). "United Kingdom: Mark Walport to Take Reins at Wellcome Trust". Science 299 (5608): 803a–. doi:10.1126/science.299.5608.803a. PMID 12574591. 
  4. ^ a b Callaway, E. (2012). "Britain names next chief science adviser: Immunologist Mark Walport, head of one of the world’s largest biomedical charities, will take on role in 2013.". Nature 487 (7405): 20. doi:10.1038/487020a. 
  5. ^ a b c "Sir Mark Walport FRS | Royal Society". Retrieved 2012-07-05. 
  6. ^ a b c d "Dr Sir Mark Walport". Debrett's People of Today. Retrieved 14 February 2012. 
  7. ^ Mayor, S. (2012). "Mark Walport will be next UK government chief scientific adviser, cabinet office announces". BMJ 345: e4621. doi:10.1136/bmj.e4621. PMID 22767620. 
  8. ^ Kain, K. H. (2010). "Funding scientific discovery: An interview with Sir Mark Walport". Disease Models & Mechanisms 3 (5–6): 265–267. doi:10.1242/dmm.005710. PMID 20427555. 
  9. ^ Anon (2012). "Good advice: The UK government's latest appointment offers hope for British science.". Nature 487 (7405): 5–6. doi:10.1038/487005b. 
  10. ^ Gibney, Elizabeth (29 June 2012). "New chief scientific adviser announced". Times Higher Education. 
  11. ^ Mark Walport's publications indexed by the Scopus bibliographic database, a service provided by Elsevier. (subscription required)
  12. ^ Sir Mark Walport in conversation with David Cleevely, Centre for Science and Policy (CSaP) University of Cambridge on YouTube
  13. ^ Boulton, G.; Rawlins, M.; Vallance, P.; Walport, M. (2011). "Science as a public enterprise: The case for open data". The Lancet 377 (9778): 1633–1635. doi:10.1016/S0140-6736(11)60647-8. 
  14. ^ Mark Walport on Twitter
  15. ^ Morris, K. (2003). "Mark Walport". The Lancet 362 (9382): 498–499. doi:10.1016/S0140-6736(03)14090-1. PMID 12927451. 
  16. ^ Walport, Mark Jeremy (1986). The biology of complement receptors (PhD thesis). University of Cambridge. 
  17. ^ "Mark Walport, Ph.D.,MB. BChir. , Member, Scientific Board". Grand Challenges in Global Health. Retrieved 14 February 2012. 
  18. ^ Walport, M.; Foulkes, I.; Weissberg, P.; Morgan, D.; Nebhrajani, S. (2012). "Medical research: No catch to UK charity funding". Nature 482 (7385): 308. doi:10.1038/482308a. PMID 22337042. 
  19. ^ Collins, P. Y.; Patel, V.; Joestl, S. S.; March, D.; Insel, T. R.; Daar, A. S.; Scientific Advisory Board the Executive Committee of the Grand Challenges on Global Mental Health; Bordin, I. A.; Anderson, E. J.; Dhansay, M.; Phillips, C.; Shurin, R. I.; Walport, W.; Ewart, Y.; Savill, S. E.; Bordin, K.; Costello, S.; Durkin, S.; Fairburn, A.; Glass, A.; Hall, A.; Huang, M. M.; Hyman, V.; Jamison, B. J.; Kaaya, S.; Kapur, P. A.; Kleinman, D. J.; Ogunniyi, W.; Otero-Ojeda, M. A.; Poo, W.; Ravindranath, A. (2011). "Grand challenges in global mental health". Nature 475 (7354): 27–30. doi:10.1038/475027a. PMC 3173804. PMID 21734685. 
  20. ^ Yamada, T.; Dautry, A.; Walport, M. (2008). "Ready for avian flu?". Nature 454 (7201): 162. doi:10.1038/454162a. PMID 18615064. 
  21. ^ Pickering, M. C.; Warren, J.; Rose, K. L.; Carlucci, F.; Wang, Y.; Walport, M. J.; Cook, H. T.; Botto, M. (2006). "Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice". Proceedings of the National Academy of Sciences 103 (25): 9649–9654. doi:10.1073/pnas.0601094103. PMC 1476693. PMID 16769899. 
  22. ^ Brown, J. S.; Hussell, T.; Gilliland, S. M.; Holden, D. W.; Paton, J. C.; Ehrenstein, M. R.; Walport, M. J.; Botto, M. (2002). "The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice". Proceedings of the National Academy of Sciences 99 (26): 16969–16974. doi:10.1073/pnas.012669199. PMC 139253. PMID 12477926. 
  23. ^ Botto, M.; Fong, K. Y.; So, A. K.; Barlow, R.; Routier, R.; Morley, B. J.; Walport, M. J. (1992). "Homozygous hereditary C3 deficiency due to a partial gene deletion". Proceedings of the National Academy of Sciences of the United States of America 89 (11): 4957–4961. doi:10.1073/pnas.89.11.4957. PMC 49207. PMID 1350678. 
  24. ^ Taylor, P. R.; Carugati, A.; Fadok, V. A.; Cook, H. T.; Andrews, M.; Carroll, M. C.; Savill, J. S.; Henson, P. M.; Botto, M.; Walport, M. J. (2000). "A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo". Journal of Experimental Medicine 192 (3): 359–366. doi:10.1084/jem.192.3.359. PMC 2193213. PMID 10934224. 
  25. ^ "Senior officials 'high earners' salaries as at 30 September 2015 - GOV.UK". www.gov.uk. 2015-12-17. Retrieved 2016-02-28. 
Government offices
Preceded by
Sir John Beddington
Government Chief Scientific Adviser
2013–present
Incumbent
Cultural offices
Preceded by
Michael Dexter
Director of Wellcome Trust
2003–2013
Succeeded by
Jeremy Farrar